These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

574 related articles for article (PubMed ID: 33098025)

  • 1. In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1.
    Rubins DJ; Meng X; McQuade P; Klimas M; Getty K; Lin SA; Connolly BM; O'Malley SS; Haley H; Purcell M; Gantert L; Holahan M; Lindgren J; Eklund P; Ekblad C; Frejd FY; Hostetler ED; González Trotter DE; Evelhoch JL
    Mol Imaging Biol; 2021 Apr; 23(2):241-249. PubMed ID: 33098025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vivo Imaging of the Programmed Death Ligand 1 by
    González Trotter DE; Meng X; McQuade P; Rubins D; Klimas M; Zeng Z; Connolly BM; Miller PJ; O'Malley SS; Lin SA; Getty KL; Fayadat-Dilman L; Liang L; Wahlberg E; Widmark O; Ekblad C; Frejd FY; Hostetler ED; Evelhoch JL
    J Nucl Med; 2017 Nov; 58(11):1852-1857. PubMed ID: 28588151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy.
    Zhu S; Liang B; Zhou Y; Chen Y; Fu J; Qiu L; Lin J
    Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):625-640. PubMed ID: 37878029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [
    Wang Y; Zhang Y; Chen Y; Wang S; Liu W; Liu Z; Hu M
    Eur J Nucl Med Mol Imaging; 2024 Sep; 51(11):3161-3175. PubMed ID: 38713298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody.
    Lv G; Sun X; Qiu L; Sun Y; Li K; Liu Q; Zhao Q; Qin S; Lin J
    J Nucl Med; 2020 Jan; 61(1):117-122. PubMed ID: 31253743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and Evaluation of [
    Huang J; Bai L; Shi D; Jiang W; Chen P; Dong Y; Zhang X; Peng J; Hou J; Lu Y; Huang X; Tang G; Huang S
    Mol Pharm; 2024 May; 21(5):2425-2434. PubMed ID: 38554143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with
    Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X
    Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative study of [
    Bai L; Sun P; Huang S; Shi D; Cheng K; Cai Z; Dong Y; Tang G
    Bioorg Chem; 2024 Oct; 151():107660. PubMed ID: 39079391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo positron emission tomography imaging for PD-L1 expression in cancer using aptamer.
    Choi YJ; Park JY; Cho YL; Chae JR; Cho H; Kang WJ
    Biochem Biophys Res Commun; 2022 Sep; 620():105-112. PubMed ID: 35780578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-in-Humans Evaluation of a PD-L1-Binding Peptide PET Radiotracer in Non-Small Cell Lung Cancer Patients.
    Zhou X; Jiang J; Yang X; Liu T; Ding J; Nimmagadda S; Pomper MG; Zhu H; Zhao J; Yang Z; Li N
    J Nucl Med; 2022 Apr; 63(4):536-542. PubMed ID: 34326125
    [No Abstract]   [Full Text] [Related]  

  • 11. Immuno-PET imaging of
    Liu Q; Jiang L; Li K; Li H; Lv G; Lin J; Qiu L
    Cancer Immunol Immunother; 2021 Jun; 70(6):1721-1733. PubMed ID: 33386467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and Biologic Evaluation of a Novel
    Donnelly DJ; Smith RA; Morin P; Lipovšek D; Gokemeijer J; Cohen D; Lafont V; Tran T; Cole EL; Wright M; Kim J; Pena A; Kukral D; Dischino DD; Chow P; Gan J; Adelakun O; Wang XT; Cao K; Leung D; Bonacorsi SJ; Hayes W
    J Nucl Med; 2018 Mar; 59(3):529-535. PubMed ID: 29025984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of [
    Liu N; Wan Q; Wu X; Zhao T; Jakobsson V; Yuan H; Chen X; Zhang J; Zhang W
    Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1685-1697. PubMed ID: 38246909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and Preclinical Evaluation of a
    Robu S; Richter A; Gosmann D; Seidl C; Leung D; Hayes W; Cohen D; Morin P; Donnelly DJ; Lipovšek D; Bonacorsi SJ; Smith A; Steiger K; Aulehner C; Krackhardt AM; Weber WA
    J Nucl Med; 2021 Sep; 62(9):1228-1234. PubMed ID: 33517324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical evaluation and pilot clinical study of [
    Ma X; Zhou X; Hu B; Li X; Yao M; Li L; Qin X; Li D; Yao Y; Hou X; Liu S; Chen Y; Wang Z; Zhou W; Li N; Zhu H; Jia B; Yang Z
    Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):3838-3850. PubMed ID: 37555904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET imaging of CXCR4 expression using [
    Cheng K; Wang S; Liu T; Pei J; Wang S; Liu J; Zhao K; Luo Y; Xu S; Yu J; Liu J
    Theranostics; 2024; 14(16):6337-6349. PubMed ID: 39431004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [
    Zhou M; Xiang S; Zhao Y; Tang Y; Yang J; Yin X; Tian J; Hu S; Du Y
    Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):369-379. PubMed ID: 37759096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical and first-in-human evaluation of
    Zhou M; Wang X; Chen B; Xiang S; Rao W; Zhang Z; Liu H; Fang J; Yin X; Deng P; Zhang X; Hu S
    Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4312-4324. PubMed ID: 35831714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Imaging of PD-L1 Expression and Dynamics with the Adnectin-Based PET Tracer
    Stutvoet TS; van der Veen EL; Kol A; Antunes IF; de Vries EFJ; Hospers GAP; de Vries EGE; de Jong S; Lub-de Hooge MN
    J Nucl Med; 2020 Dec; 61(12):1839-1844. PubMed ID: 32358092
    [No Abstract]   [Full Text] [Related]  

  • 20. Probody Therapeutic Design of
    Giesen D; Broer LN; Lub-de Hooge MN; Popova I; Howng B; Nguyen M; Vasiljeva O; de Vries EGE; Pool M
    Clin Cancer Res; 2020 Aug; 26(15):3999-4009. PubMed ID: 31953313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.